Lamm D L, DeHaven J I, Riggs D R, Delgra C, Burrell R
Department of Urology, West Virginia University School of Medicine, Morgantown 26506.
Urol Res. 1993 Jan;21(1):33-7. doi: 10.1007/BF00295189.
The current treatment of choice for superficial bladder cancer, bacillus Calmette-Guérin, has significant adverse side effects. We have compared two alternative immunotherapies--crude keyhole limpet hemocyanin (KLH) and Immucothel, a KLH modified for clinical use (Biosyn)--in an intralesional mouse model of bladder cancer (MBT2). Crude KLH required either immunization before tumor transplant or frequent intralesional therapy after transplantation to be effective. In addition, Immucothel required pre-immunization to be effective, and increasing the frequency and dosage of post-transplant immunization was not effective without pre-immunization. Preliminary investigations into the KLH-induced anti-tumor mechanism(s) suggest that natural killer cell activity may be involved. Both crude KLH and Immucothel appear to be effective immunotherapies of use in the treatment of transitional cell carcinoma.
目前浅表性膀胱癌的首选治疗方法——卡介苗，有显著的不良副作用。我们在膀胱癌（MBT2）的瘤内小鼠模型中比较了两种替代免疫疗法——粗制钥孔戚血蓝蛋白（KLH）和Immucothel（一种经临床使用改良的KLH，Biosyn公司生产）。粗制KLH要么在肿瘤移植前进行免疫，要么在移植后频繁进行瘤内治疗才有效。此外，Immucothel需要预先免疫才有效，并且在没有预先免疫的情况下，增加移植后免疫的频率和剂量是无效的。对KLH诱导的抗肿瘤机制的初步研究表明，自然杀伤细胞活性可能参与其中。粗制KLH和Immucothel似乎都是治疗移行细胞癌有效的免疫疗法。
